Analysis of Correlation Between Serum Oncostatin-M and Disease Severity and Mortality in Hospitalized Patients with Community-Acquired Pneumonia

References

• Sun Y, Li H, Pei Z, et al. Incidence of community-acquired pneumonia in urban China: a national population-based study. Vaccine. 2020;38(52):8362–8370. doi:10.1016/j.vaccine.2020.11.004
   PubMed Web of Science ®Google Scholar
• Zarling JM, Shoyab M, Marquardt H, et al. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc National Acad Sci United States Am. 1986;83(24):9739–9743. doi:10.1073/pnas.83.24.9739
   PubMed Web of Science ®Google Scholar
• Malik N, Kallestad JC, Gunderson NL, et al. Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol. 1989;9(7):2847–2853. doi:10.1128/mcb.9.7.2847-2853.1989
   PubMed Web of Science ®Google Scholar
• Friedrich M, Höss N, Stögbauer F, et al. Complete inhibition of in vivo glioma growth by oncostatin M. J Neurochemistry. 2001;76(5):1589–1592. doi:10.1046/j.1471-4159.2001.00202.x
   PubMed Web of Science ®Google Scholar
• Kim MS, Louwagie J, Carvalho NL, et al. Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS One. 2009;4(8):e6555. doi:10.1371/journal.pone.0006555
   PubMed Web of Science ®Google Scholar
• Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene. 2008;27(20):2801–2809. doi:10.1038/sj.onc.1210950
   PubMed Web of Science ®Google Scholar
• Verstockt S, Verstockt B, Machiels K, et al. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. Inflammatory bowel dis. 2021;27(10):1564–1575. doi:10.1093/ibd/izab032
   PubMed Web of Science ®Google Scholar
• West NR, Hegazy AN, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nature Med. 2017;23(5):579–589. doi:10.1038/nm.4307
   PubMed Web of Science ®Google Scholar
• Gong Y, Yan X, Sun X, et al. Oncostatin M Is a Prognostic Biomarker and Inflammatory Mediator for Sepsis. J Infectious Dis. 2020;221(12):1989–1998. doi:10.1093/infdis/jiaa009
   PubMed Web of Science ®Google Scholar
• Young PY, Mueller TF, Sis B, et al. Oncostatin M Plays a Critical Role in Survival after Acute Intestinal Ischemia: reperfusion Injury. Surgical Infections. 2020;21(9):799–806. doi:10.1089/sur.2019.193
   PubMed Web of Science ®Google Scholar
• Mozaffarian A, Brewer AW, Trueblood ES, et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol. 2008;181(10):7243–7253. doi:10.4049/jimmunol.181.10.7243
   PubMed Web of Science ®Google Scholar
• Botelho FM, Rangel-Moreno J, Fritz D, et al. Pulmonary expression of oncostatin M (OSM) promotes inducible BALT formation independently of IL-6, despite a role for IL-6 in OSM-driven pulmonary inflammation. J Immunol. 2013;191(3):1453–1464. doi:10.4049/jimmunol.1203318
   PubMed Web of Science ®Google Scholar
• Machiyama T, So T, Okuyama Y, et al. TNF receptor associated factor 5 controls oncostatin M-mediated lung inflammation. Biochem. Biophys. Res. Commun. 2018;499(3):544–550. doi:10.1016/j.bbrc.2018.03.186
   PubMed Web of Science ®Google Scholar
• Traber KE, Hilliard KL, Allen E, et al. Induction of STAT3-Dependent CXCL5 Expression and Neutrophil Recruitment by Oncostatin-M during Pneumonia. Am. J. Respir. Cell Mol. Biol. 2015;53(4):479–488. doi:10.1165/rcmb.2014-0342OC
   PubMed Web of Science ®Google Scholar
• Cao B, Huang Y, She DY, et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J. 2018;12(4):1320–1360. doi:10.1111/crj.12674
   PubMed Web of Science ®Google Scholar
• Sligl WI, Marrie TJ. Severe community-acquired pneumonia. Critical Care Clinics. 2013;29(3):563–601. doi:10.1016/j.ccc.2013.03.009
   PubMed Web of Science ®Google Scholar
• Welte T. Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. Eur j Clin Microbiol Infect Dis. 2012;31(1):33–47. doi:10.1007/s10096-011-1272-4
   PubMed Web of Science ®Google Scholar
• Arunachalam PS, Wimmers F, Mok CKP, et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369(6508):1210–1220. doi:10.1126/science.abc6261
   PubMed Web of Science ®Google Scholar
• Tserel L, Jõgi P, Naaber P, et al. Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals. Front Immunol. 2021;12:709759. doi:10.3389/fimmu.2021.709759
   PubMed Web of Science ®Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–e67. doi:10.1164/rccm.201908-1581ST
   PubMed Web of Science ®Google Scholar
• Bradley J, Sbaih N, Chandler TR, et al. Pneumonia Severity Index and CURB-65 Are Good Predictors of Mortality in Hospitalized Patients with SARS-CoV-2 Community-Acquired Pneumonia. Chest. 2021;2:565.
   Google Scholar
• García Clemente MM, Herrero Huertas J, Fernández Fernández A, et al. Assessment of risk scores in Covid-19. Int J Clin Pract. 2021;75(12):e13705. doi:10.1111/ijcp.13705
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Eng j Med. 1997;336(4):243–250. doi:10.1056/NEJM199701233360402
   PubMed Web of Science ®Google Scholar
• Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377–382. doi:10.1136/thorax.58.5.377
   PubMed Web of Science ®Google Scholar
• Wang JL, Chen X, Xu Y, et al. The Associations of Serum IL-37 With the Severity and Prognosis in Patients With Community-Acquired Pneumonia: a Retrospective Cohort Study. Front Immunol. 2021;12:636896. doi:10.3389/fimmu.2021.636896
   PubMed Web of Science ®Google Scholar
• Feng CM, Wang XM, Li MD, et al. Serum interleukin-17 predicts severity and prognosis in patients with community acquired pneumonia: a prospective cohort study. BMC Pulmonary Med. 2021;21(1):393. doi:10.1186/s12890-021-01770-6
   PubMed Web of Science ®Google Scholar
• Song S, Jia Q, Chen X, et al. Serum suPAR associated with disease severity and mortality in elderly patients with community-acquired pneumonia. Scandinavian j Clin Lab Investigation. 2020;80(6):515–522. doi:10.1080/00365513.2020.1795920
   PubMed Web of Science ®Google Scholar
• Luo Q, He X, Zheng Y, et al. Elevated progranulin as a novel biomarker to predict poor prognosis in community-acquired pneumonia. J Infection. 2020;80(2):167–173. doi:10.1016/j.jinf.2019.12.004
   PubMed Web of Science ®Google Scholar